Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Huaibao Feng

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Contemporary Clinical Trials|April 17, 2007
Group sequential t-test for clinical trials with small sample sizes across stagesJun Shao, Huaibao Feng
Journal of Biopharmaceutical Statistics|June 2, 2012
Adaptive group sequential test with changing patient populationHuaibao Feng, Qing Liu
Journal of Biopharmaceutical Statistics|November 21, 2007
Adaptive group sequential test for clinical trials with changing patient populationHuaibao Feng, Jun Shao, Shein-Chung Chow
Clinical Lymphoma, Myeloma & Leukemia|February 24, 2019
Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular LymphomaGilles Salles, Ajay K Gopal, Monique C Minnema, et al.
Clinical Pharmacology and Therapeutics|February 12, 2025
Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B-Cell LymphomaTommy Li, Leonid Gibiansky, Apurvasena Parikh, et al.
Haematologica|June 13, 2012
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myelomaBertrand Arnulf, Halyna Pylypenko, Sebastian Grosicki, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 22, 2017
Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple MyelomaAjai Chari, Suzanne Arinsburg, Sundar Jagannath, et al.
Clinical Pharmacokinetics|November 18, 2011
Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphomaAndrzej Hellmann, Simon Rule, Jan Walewski, et al.
Clinical Pharmacokinetics|December 21, 2024
Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin LymphomaTommy Li, Leonid Gibiansky, Apurvasena Parikh, et al.
Haematologica|January 18, 2015
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 studyPhilippe Moreau, Halyna Pylypenko, Sebastian Grosicki, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Contemporary Clinical Trials|April 17, 2007
Group sequential t-test for clinical trials with small sample sizes across stagesJun Shao, Huaibao Feng
Journal of Biopharmaceutical Statistics|June 2, 2012
Adaptive group sequential test with changing patient populationHuaibao Feng, Qing Liu
Journal of Biopharmaceutical Statistics|November 21, 2007
Adaptive group sequential test for clinical trials with changing patient populationHuaibao Feng, Jun Shao, Shein-Chung Chow
Clinical Lymphoma, Myeloma & Leukemia|February 24, 2019
Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular LymphomaGilles Salles, Ajay K Gopal, Monique C Minnema, et al.
Clinical Pharmacology and Therapeutics|February 12, 2025
Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B-Cell LymphomaTommy Li, Leonid Gibiansky, Apurvasena Parikh, et al.
Haematologica|June 13, 2012
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myelomaBertrand Arnulf, Halyna Pylypenko, Sebastian Grosicki, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 22, 2017
Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple MyelomaAjai Chari, Suzanne Arinsburg, Sundar Jagannath, et al.
Clinical Pharmacokinetics|November 18, 2011
Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphomaAndrzej Hellmann, Simon Rule, Jan Walewski, et al.
Clinical Pharmacokinetics|December 21, 2024
Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin LymphomaTommy Li, Leonid Gibiansky, Apurvasena Parikh, et al.
Haematologica|January 18, 2015
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 studyPhilippe Moreau, Halyna Pylypenko, Sebastian Grosicki, et al.
Pageof 3